ACAP2

Across TCGA pan-cancer cohorts, ACAP2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ACAP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ACAP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACAP2 is over-expressed in tumor, although a few such as COAD and UCEC show the opposite, repressed pattern.

KIRC, LIHC, and LUSC are the cancer types where ACAP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACAP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.443	<.001	10	view →
LIHC	Female	II,III,IV	+0.754	<.001	8	view →
LUSC	All	All	+0.964	<.001	6	view →
HNSC	All	All	+0.659	<.001	6	view →
BLCA	All	All	+0.501	.006	6	view →
CHOL	All	All	+1.361	<.001	5	view →
COAD	All	All	−0.465	<.001	4	view →
UCEC	All	All	−0.662	.004	2	view →
KICH	All	All	−0.464	.022	2	view →
LUAD	Female	II,III,IV	−0.438	.007	1	view →
READ	All	All	−0.378	.049	1	view →
THCA	All	All	−0.240	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ACAP2–KIRC

Open the KIRC breakdown →